NO20052846L - HPV-16 og -18 L1 VLP vaksine. - Google Patents

HPV-16 og -18 L1 VLP vaksine.

Info

Publication number
NO20052846L
NO20052846L NO20052846A NO20052846A NO20052846L NO 20052846 L NO20052846 L NO 20052846L NO 20052846 A NO20052846 A NO 20052846A NO 20052846 A NO20052846 A NO 20052846A NO 20052846 L NO20052846 L NO 20052846L
Authority
NO
Norway
Prior art keywords
hpv
vlp vaccine
vlp
vaccine
vlps
Prior art date
Application number
NO20052846A
Other languages
English (en)
Norwegian (no)
Inventor
Martine Anne Cecil Wettendorff
Gary Dubin
Bruce Innis
Moncef Mohammed Slaoui
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of NO20052846L publication Critical patent/NO20052846L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20052846A 2002-12-20 2005-06-13 HPV-16 og -18 L1 VLP vaksine. NO20052846L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43503502P 2002-12-20 2002-12-20
US49665303P 2003-08-20 2003-08-20
PCT/EP2003/014562 WO2004056389A1 (en) 2002-12-20 2003-12-18 Hpv-16 and -18 l1 vlp vaccine

Publications (1)

Publication Number Publication Date
NO20052846L true NO20052846L (no) 2005-07-13

Family

ID=32685362

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052846A NO20052846L (no) 2002-12-20 2005-06-13 HPV-16 og -18 L1 VLP vaksine.

Country Status (28)

Country Link
US (2) US20060251676A1 (cs)
EP (1) EP1572233B1 (cs)
JP (1) JP5475939B2 (cs)
KR (3) KR20120118087A (cs)
AP (1) AP2005003347A0 (cs)
AR (1) AR042530A1 (cs)
AT (1) ATE503492T1 (cs)
AU (1) AU2003293942B2 (cs)
BE (3) BE2015C069I2 (cs)
BR (1) BR0317544A (cs)
CA (1) CA2510457C (cs)
CY (1) CY1111552T1 (cs)
DE (1) DE60336581D1 (cs)
DK (1) DK1572233T3 (cs)
EA (2) EA200701633A1 (cs)
EC (1) ECSP055869A (cs)
IL (1) IL169085A (cs)
IS (1) IS2811B (cs)
MA (1) MA27581A1 (cs)
MX (1) MXPA05006764A (cs)
MY (1) MY144492A (cs)
NO (1) NO20052846L (cs)
NZ (1) NZ540811A (cs)
OA (1) OA13147A (cs)
PL (1) PL215257B1 (cs)
PT (1) PT1572233E (cs)
TW (1) TWI349557B (cs)
WO (1) WO2004056389A1 (cs)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1126876T3 (da) 1998-10-16 2007-07-02 Glaxosmithkline Biolog Sa Adjuvanssystemer og vacciner
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
WO2005123125A1 (en) * 2004-06-16 2005-12-29 Glaxosmithkline Biologicals S.A. Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52
WO2006113209A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
KR20080005585A (ko) * 2005-04-26 2008-01-14 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
JP2008539182A (ja) * 2005-04-26 2008-11-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
CN101570571B (zh) 2007-04-29 2012-07-11 北京万泰生物药业股份有限公司 截短的人乳头瘤病毒18型l1蛋白
WO2008134934A1 (en) 2007-04-29 2008-11-13 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. A truncated l1 protein of human papillomavirus 16
DK2403507T3 (en) * 2009-03-05 2018-06-06 Jenny Colleen Mccloskey TREATMENT OF INFECTION
PL2444103T3 (pl) * 2009-06-19 2018-05-30 Eyegene Inc. Szczepionka przeciwko rakowi szyjki macicy
CN106461667A (zh) 2014-01-31 2017-02-22 乌利塞生物医药公司 用于检测感染及相关病症的生物传感器
IL251825B2 (en) 2014-10-24 2023-09-01 Hpvvax Llc Treatment of cancer and skin damage
US10799574B2 (en) 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
WO2016194685A1 (ja) * 2015-06-02 2016-12-08 テルモ株式会社 アルミニウムを含有するアジュバント組成物およびこれを含むワクチン組成物
EP3762010A4 (en) 2018-03-06 2022-04-06 Precigen, Inc. HEPATITIS B VACCINES AND USES THEREOF
IL314393A (en) 2018-03-06 2024-09-01 Precigen Inc Human papillomavirus vaccines and uses of the same
CN110551182A (zh) * 2018-06-04 2019-12-10 厦门大学 一种人乳头瘤病毒18型l1蛋白的突变体
AU2019393770B2 (en) 2018-12-03 2025-02-20 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332596A1 (de) * 1993-09-24 1995-03-30 Martin Josef Dr Sapp Monoklonale Antikörper
DE69835294T2 (de) 1997-09-05 2007-07-26 Medimmune, Inc. Methode zur in vitro auseinander- und wiederzusammensetzung von papillomavirus virusähnlichen teilchen (vlps)
DE60040727D1 (de) * 1999-02-05 2008-12-18 Merck & Co Inc Menschliche papillomavirus impfstoff-formulierungen
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
DK1296711T3 (da) * 2000-06-26 2006-08-28 Stressgen Biotechnologies Corp HPV-E7 til behandling af humant papillomavirus

Also Published As

Publication number Publication date
IL169085A0 (en) 2007-07-04
AP2005003347A0 (en) 2005-06-30
TW200423957A (en) 2004-11-16
IL169085A (en) 2014-04-30
MXPA05006764A (es) 2005-09-08
KR101361769B1 (ko) 2014-02-10
BE2015C067I2 (cs) 2024-08-08
JP5475939B2 (ja) 2014-04-16
EA200500834A1 (ru) 2006-02-24
MA27581A1 (fr) 2005-10-03
BE2015C069I2 (cs) 2024-08-08
CA2510457A1 (en) 2004-07-08
BR0317544A (pt) 2005-11-22
AR042530A1 (es) 2005-06-22
MY144492A (en) 2011-09-30
NZ540811A (en) 2007-03-30
DE60336581D1 (de) 2011-05-12
KR20050086924A (ko) 2005-08-30
IS2811B (is) 2012-11-15
BE2015C068I2 (cs) 2024-08-08
PT1572233E (pt) 2011-06-07
AU2003293942B2 (en) 2009-12-10
TWI349557B (en) 2011-10-01
PL377710A1 (pl) 2006-02-06
EA200701633A1 (ru) 2007-12-28
KR20120118087A (ko) 2012-10-25
EP1572233B1 (en) 2011-03-30
EP1572233A1 (en) 2005-09-14
US20060251676A1 (en) 2006-11-09
HK1085378A1 (en) 2006-08-25
PL215257B1 (pl) 2013-11-29
JP2006512413A (ja) 2006-04-13
US20050287161A1 (en) 2005-12-29
CY1111552T1 (el) 2015-08-05
CA2510457C (en) 2011-12-06
ECSP055869A (es) 2005-09-20
OA13147A (en) 2006-12-13
DK1572233T3 (da) 2011-06-27
WO2004056389A1 (en) 2004-07-08
AU2003293942A1 (en) 2004-07-14
ATE503492T1 (de) 2011-04-15
KR20120123616A (ko) 2012-11-08
EA009179B1 (ru) 2007-12-28
IS7885A (is) 2005-06-09

Similar Documents

Publication Publication Date Title
NO20052846L (no) HPV-16 og -18 L1 VLP vaksine.
ECSP045300A (es) Antígenos virales
HUP0301180A2 (hu) Imidazokinolinaminok adjuvánsként való használata DNS vakcinálásban
DE60110822D1 (de) Zubereitung zur immunisierung gegen den aids-virus
WO2007121894A3 (en) Hpv-18-based papillomavirus vaccine
WO2007121895A3 (en) Hpv-16-based papillomavirus vaccine
WO2002087614A3 (en) Multivalent vaccine comprising an hiv antigen and an hsv antigen and/or an hpv antigen
CY1111521T1 (el) Λοιμογονος συστηματικος καλυκοϊος αιλουροειδων
FR15C0084I2 (fr) Vaccin contre les virus hpv16 et hpv18 et au moins un autre type de hpv selectionne parmi hpv 31, 45 ou 52
EP1670507A4 (en) VACCINE FOR THE TREATMENT AND PREVENTION OF HERPES SIMPLEX VIRUS INFECTION
DE60305884D1 (de) Igg3 immunogloblin als schutzsmarker gegen viren infektiösen krankheiten und seine verwendungen
BR0209251A (pt) Vacina contra vìrus da febre aftosa
DE60236806D1 (de) Transkutane immunisierung gegen papillomavirus mit virusähnlichen papillomaviruspartikeln
WO2007076091A3 (en) Treatment of viral infections using a tissue factor inhibitor
DE60305279D1 (de) Verwendung von Methyltestosteron zur Behandlung von menschlichen Papillomavirus Infektionen
AR041515A1 (es) Vacuna a dna contra el virus de papiloma humano
NO20072498L (no) Behandling eller forebyggelse av blodende virale infeksjoner med immunmodulatorforbindelse
AR053715A1 (es) Vacuna multivalente de vph
DE60238554D1 (de) Vakzine gegen infektionskrankheiten
SI1572233T1 (sl) Uporaba HPV16 in HPV18 kot cepivo proti enemu ali več onkogenih HPV tipa 31,33,35,39,45,51,52,56,58,59,66,68
RU2004107082A (ru) Штамм "ильиногорский" вируса трансмиссивного гастроэнтерита свиней для изготовления диагностических и вакцинных препаратов
DE60040792D1 (de) Stress-protein-peptidkomplexe als impfstoffe gegen intrazelluläre pathogene
RU2004106894A (ru) Штамм "ленинградский" вируса трансмиссивного гастроэнтерита свиней для изготовления диагностических и вакцинных препаратов
ATE467424T1 (de) Escape-mutanten des newcastle-disease-virus als marker-vakzine
BR0309603A (pt) Polipeptìdeo e7 mutado de hpv-16, composição farmacêutica que o compreende e seu processo de preparação

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application